Efficacy of cisplatin plus paclitaxel as chemotherapy in patients with cervical cancer after laparoscopic nerve-sparing extensive hysterectomy and its effect on immune function
Zhang, J.; Song, C.; Liu, B.
Pakistan Journal of Pharmaceutical Sciences 35(1(Special): 355-359
2022
ISSN/ISBN: 1011-601X PMID: 35236647 Document Number: 18294
To investigate the value of cisplatin plus paclitaxel in patients with middle and advanced cervical cancer after laparoscopic nerve-sparing extensive hysterectomy and its effect on their T lymphocyte subsets. 44 patients with middle and advanced cervical cancer were randomly divided into the control group (n = 22) and the observation group (n = 22). Patients in the control group received nab-paclitaxel as chemotherapy, while patients in the observation group received cisplatin plus nab-paclitaxel as adjuvant therapy. The local recurrence and distant metastasis rates were statistically analyzed after 1 year of follow-up. The overall effective rate in the observation group was significantly higher than that in the control group (P<0.05). The serum levels of IL-4, IL-10 and TNF-α in the two groups were reduced markedly after treatment than before treatment (P<0.05) and the observation group was significantly lower than the control group (P<0.05). After treatment, the proportion of CD3+ and CD4+ cells increased, the proportion of CD8+ cells decreased more significantly than that in the control group (P<0.05). The combination of cisplatin and paclitaxel was demonstrated to have obviously synergistic and attenuated effects after middle and advanced cervical cancer surgery, optimize the efficacy, reduce adverse effects, and improve the body's immune function.
Document emailed within 1 workday
